Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?
There has been growing interest in targeting myocardial substrate metabolism for the therapy of cardiovascular and metabolic diseases. This is largely based on the observation that cardiac metabolism undergoes significant changes during both physiologic and pathologic stresses. In search for an effective therapeutic strategy, recent studies have focused on the functional significance of the substrate switch in the heart during stress conditions, such as cardiac hypertrophy and failure, using both pharmacologic and genetic approaches. The results of these studies indicate that both the capacity and the flexibility of the cardiac metabolic network are essential for normal function; thus, their maintenance should be the primary goal for future metabolic therapy.
Kolwicz
Stephen C
SC
Mitochondria and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98109, USA.
Tian
Rong
R
D000818:Animals; D006332:Cardiomegaly / Q000378:metabolism / Q000628:therapy; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D004734:Energy Metabolism / Q000187:drug effects* / Q000235:genetics*; D005227:Fatty Acids / Q000378:metabolism; D015316:Genetic Therapy; D005838:Genotype; D006333:Heart Failure / Q000378:metabolism / Q000628:therapy; D006801:Humans; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D010641:Phenotype
D002317:Cardiovascular Agents; D005227:Fatty Acids